Scholarlink

Background <p>The phrase filler fatigue has gained traction in magazines, social media, and corporate commentary, invoked as though it represents an empirical decline in dermal filler use. Yet its clinical validity, cultural meaning, and market implications remain contested.</p> Methods <p>We conducted a multi-layered analysis of peer-reviewed literature, 18,940 newspaper and magazine articles, 2.3&#xa0;million social media posts, and financial disclosures from major aesthetics firms (AbbVie, Galderma, Revance–Teoxane, Hugel, Merz, Croma). Analytical techniques included natural language processing, sentiment and topic modelling, structural break and diffusion analyses, comparative corporate statistics, and exploratory scenario modelling. Findings were synthesised using a punctuated equilibrium framework.</p> Results <p>The peer-reviewed scientific literature does not contain an indexed article using the specific term ‘filler fatigue’. Magazines and newspapers used the term in 742 articles (3.9% of filler coverage), concentrated in North America and Europe, with 58% adopting a negative tone. Social media analysis revealed 14,203 #fillerfatigue posts but far greater activity around #fillergonewrong (91,552) and #naturalbeauty (&gt; 220,000). Sentiment diverged geographically: net negative in North America (–32 pp), balanced in Europe (–6 pp), and strongly positive in Asia (+ 38 pp). Economically, AbbVie’s Juvéderm portfolio showed reported decline (–24% YoY in Q2 2025), while competitors reported double-digit growth (Galderma + 12.2%, Hugel + 17.7%, Merz Korea + 50%). Across the observed quarters, AbbVie’s reported growth trajectory differed from the peer group in the available disclosures (comparative tests reported; interpretation bounded by segment comparability). Exploratory scenario modelling was consistent with recent disclosed trends, while remaining highly uncertain given short time series. Across domains, discourse punctuations in 2021, 2022, and 2023 coincided with spikes in negative media but did not align with evidence of a uniform, multi-firm market contraction.</p> Conclusions <p>Filler fatigue is not a clinical diagnosis but a cultural construct, disproportionately amplified in Western media. Market data indicate redistribution rather than retreat, with consumers shifting toward moderation, authenticity, and brand trust. Level of Evidence: not gradable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

“Filler fatigue”: media narratives, industry rhetoric, and the emergence of “filler consciousness” in aesthetic medicine

  • 期刊论文

  • 发表日期：

    2026年5月11日

查看全文
  • Eqram Rahman,
  • Alain Michon,
  • Parinitha Rao,
  • Patricia E Garcia,
  • Sotirios Ioannidis,
  • Alexander Nassif,
  • William Richard Webb,
  • Wolfgang G Philipp-Dormston

摘要

Background

The phrase filler fatigue has gained traction in magazines, social media, and corporate commentary, invoked as though it represents an empirical decline in dermal filler use. Yet its clinical validity, cultural meaning, and market implications remain contested.

Methods

We conducted a multi-layered analysis of peer-reviewed literature, 18,940 newspaper and magazine articles, 2.3 million social media posts, and financial disclosures from major aesthetics firms (AbbVie, Galderma, Revance–Teoxane, Hugel, Merz, Croma). Analytical techniques included natural language processing, sentiment and topic modelling, structural break and diffusion analyses, comparative corporate statistics, and exploratory scenario modelling. Findings were synthesised using a punctuated equilibrium framework.

Results

The peer-reviewed scientific literature does not contain an indexed article using the specific term ‘filler fatigue’. Magazines and newspapers used the term in 742 articles (3.9% of filler coverage), concentrated in North America and Europe, with 58% adopting a negative tone. Social media analysis revealed 14,203 #fillerfatigue posts but far greater activity around #fillergonewrong (91,552) and #naturalbeauty (> 220,000). Sentiment diverged geographically: net negative in North America (–32 pp), balanced in Europe (–6 pp), and strongly positive in Asia (+ 38 pp). Economically, AbbVie’s Juvéderm portfolio showed reported decline (–24% YoY in Q2 2025), while competitors reported double-digit growth (Galderma + 12.2%, Hugel + 17.7%, Merz Korea + 50%). Across the observed quarters, AbbVie’s reported growth trajectory differed from the peer group in the available disclosures (comparative tests reported; interpretation bounded by segment comparability). Exploratory scenario modelling was consistent with recent disclosed trends, while remaining highly uncertain given short time series. Across domains, discourse punctuations in 2021, 2022, and 2023 coincided with spikes in negative media but did not align with evidence of a uniform, multi-firm market contraction.

Conclusions

Filler fatigue is not a clinical diagnosis but a cultural construct, disproportionately amplified in Western media. Market data indicate redistribution rather than retreat, with consumers shifting toward moderation, authenticity, and brand trust. Level of Evidence: not gradable.